A model-based illustrative exploratory approach to optimize the dosing of Peg-IFN/RBV in cirrhotic hepatitis C patients treated with triple therapy

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 1, 2015, Pages 37-40

  Laouenan C ^a,b   Guedj, J ^a   Peytavin, G ^a,b   Tram Nguyen, T H ^a   Lapalus, M ^a   Khelifa Mouri, F ^c   Boyer, N ^c   Zoulim, F ^d,e   Serfaty, L ^f   Bronowicki, J P ^g,h   Martinot Peignoux, M ^a   Lada, O ^a   Asselah, T ^a,c   Dorival, C ⁱ   Hezode C ^j,k   Carrat, F ^f,i   Nicot, F ^l   Marcellin, P ^a,c   Mentre F ^a,b  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c BEAUJON HOSPITAL   (France)

^d UNIVERSITÉ DE LYON   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITÉ DE LORRAINE   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ANEMIA; CHRONIC HEPATITIS C; CIRRHOTIC HEPATITIS C; CONCENTRATION AT STEADY-STATE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IC50; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TURNOVER TIME;

EID: 84936755220     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.8     Document Type: Review

References (10)

1. Hézode, C., et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J. Hepatol. 59, 434-441 (2013).
2. Hézode, C., et al,. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147, 132-142 (2014).
3. Laouénan, C., et al,. Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients. Antimicrob. Agents Chemother. 58, 5332-5341 (2014).
4. Poordad, F., et al,. Effects of ribavirin dose reduction vs. erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection - a randomized trial. Gastroenterology 145, 1035-1044 (2013).
5. Bacon, B.R., et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217 (2011).
6. Zeuzem, S., et al,. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
7. Morello, J., Rodríguez-Novoa, S., Jiménez-Nácher, I., &, Soriano, V., Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J. Antimicrob. Chemother. 62, 1174-1180 (2008).
8. Hayashi, H., Beppu, T., Shirabe, K., Maehara, Y., &, Baba, H., Management of thrombocytopenia due to liver cirrhosis: a review. World J. Gastroenterol. 20, 2595-2605 (2014).
9. De Franceschi, L., et al,. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31, 997-1004 (2000).
10. Sulkowski, M.S., Anemia in the treatment of hepatitis C virus infection. Clin. Infect. Dis. 37 (suppl. 4), S315-322 (2003).